Bile Reflux Gastropathy after Therapeutic Biliary Interventions

Bile Reflux Gastropathy: Prevalence and Risk Factors after Therapeutic Biliary Interventions: A Retrospective Cohort Study

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

PACTR

Registry ID

PACTR202111578379735

Enrollment

288

Registered

2021-11-18

Start date

2018-01-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Digestive System

Interventions

Upper GIT endoscopy in Post cholecystectomy

ERCP

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1-refractory epigastric pain and dyspeptic symptoms after therapeutic biliary interventions with 2- history of poor response to prokinetics, mucosa-protective medicines, H2-blockers and/or proton-pump inhibitors (PPI).

Exclusion criteria

Exclusion criteria: 1- unstable cardiopulmonary, neurologic, or cardiovascular status, 2- other causes of biliary diseases (CBD strictures, and hepatolithiasis), 3- structural abnormalities of the esophagus, stomach, or small intestine, 4- patients who underwent bariatric surgery out of the scope of the study, 5- patients on long-term non-steroidal analgesics, and 6- patients on oral contraceptive drugs.

Design outcomes

Primary

Measure	Time frame
- prevalence and risk factors of bile reflux Gastropathy Factors after Therapeutic Biliary Interventions, and to evaluate the gastric mucosa endoscopic and histopathologic changes.	—

Secondary

Measure	Time frame
gastric fluid aspiration for quantitative analysis of gastric aspirate total bilirubin level and pH	—

Countries

Egypt

Contacts

Public ContactAmal Dwedar

Professor

dewedaramal2021@gmail.com00201002719185

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026